Cadila Healthcare Ltd., the flagship company of the Zydus Cadila group, is counting on new launches in the US and continued strong growth in the India business to drive growth in the second half as sales of certain products like Levorphanol, an opioid painkiller, diminish on account of generic competition. It is also considering ‘strategic options’ for the Europe business, which has been slowing down.
The company plans to launch 15-16 products in the US during the second half, having already launched 15 in the...






